

Global T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumours and Other Indications), by Therapy Type (CAR T-cell Therapy, TCR-based and TIL-based), by Modality (Research and Commercialized) and Region - 2023 to 2033

Market Report | 2023-01-19 | 250 pages | Transparency Market Research

AVAILABLE LICENSES:

- Single User License \$5795.00
- Multi User License \$8795.00
- Global Site License \$11795.00

Report description:

T-cell Therapy Market - Scope of Report

TMR's report on the global T-cell therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2033. The report provides revenue of the global T-cell therapy market for the period 2017-2031, considering 2023 as the base year and 2033 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global T-cell therapy market from 2023 to 2033.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the T-cell therapy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global T-cell therapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global T-cell therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global T-cell therapy market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

The report delves into the competitive landscape of the global T-cell therapy market. Key players operating in the global T-cell therapy market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global T-cell therapy market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market T-cell therapy.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants' insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

- Industry Sources:
 - o WorldWideScience.org
 - o Elsevier, Inc.
 - o National Institutes of Health (NIH)
 - o PubMed
 - o NCBI
 - o Department of Health Care Service
- Trade Data Sources
 - o Trade Map
 - o UN Comtrade
 - o Trade Atlas
- Company Information
 - o OneSource Business Browser
 - o Hoover's
 - o Factiva
 - o Bloomberg
- Mergers & Acquisitions
 - o Thomson Mergers & Acquisitions
 - o MergerStat
 - o Profound

Primary Research

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.

Helps in validating and strengthening secondary research findings

Further develops the analysis team's expertise and market understanding

Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers

Purchasing/Sourcing managers, technical personnel, distributors

Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC

Danfysik A/S

Hitachi, Ltd.

IBA Worldwide

Mevion Medical Systems, Inc.

Data Triangulation: Information culled from "Secondary & Primary Sources" is cross-checked with "TMR Knowledge Repository", which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others

Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

Table of Contents:

1. Executive Summary

□ □ 1.1. Global Market Outlook

□ □ 1.2. Demand-side Trends

□ □ 1.3. Supply-side Trends

□ □ 1.4. Technology Roadmap Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.5. Analysis and Recommendations
- 2. Market Overview
 - 2.1. Market Coverage / Taxonomy
 - 2.2. Market Definition / Scope / Limitations
- 3. Market Background
 - 3.1. Market Dynamics
 - 3.1.1. Drivers
 - 3.1.2. Restraints
 - 3.1.3. Opportunity
 - 3.1.4. Trends
 - 3.2. Scenario Forecast
 - 3.2.1. Demand in Optimistic Scenario
 - 3.2.2. Demand in Likely Scenario
 - 3.2.3. Demand in Conservative Scenario
 - 3.3. Opportunity Map Analysis
 - 3.4. Investment Feasibility Matrix
 - 3.5. Value Chain Analysis
 - 3.5.1. Profit Margin Analysis
 - 3.5.2. Service Providers
 - 3.6. PESTLE and Porter's Analysis
 - 3.7. Regulatory Landscape
 - 3.7.1. By Key Regions
 - 3.7.2. By Key Countries
 - 3.8. Regional Parent Market Outlook
- 4. Global T-cell Therapy Market Analysis 2018-2022 and Forecast, 2023-2033
 - 4.1. Historical Market Size Value (US\$ Bn) Analysis, 2018-2022
 - 4.2. Current and Future Market Size Value (US\$ Bn) Projections, 2023-2033
 - 4.2.1. Y-o-Y Growth Trend Analysis
 - 4.2.2. Absolute \$ Opportunity Analysis
- 5. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Indication
 - 5.1. Introduction / Key Findings
 - 5.2. Historical Market Size Value (US\$ Bn) Analysis By Indication , 2018-2022
 - 5.3. Current and Future Market Size Value (US\$ Bn) Analysis and Forecast By Indication , 2023-2033
 - 5.3.1. Hematologic Malignancies
 - 5.3.1.1. Lymphoma
 - 5.3.1.2. Leukemia
 - 5.3.1.3. Myeloma
 - 5.3.2. Solid Tumors
 - 5.3.2.1. Melanoma
 - 5.3.2.2. Brain & Central Nervous System
 - 5.3.2.3. Liver Cancer
 - 5.3.2.4. Other Solid Tumors
 - 5.3.3. Other Indications
 - 5.4. Y-o-Y Growth Trend Analysis By Indication , 2018-2022
 - 5.5. Absolute \$ Opportunity Analysis By Indication , 2023-2033
- 6. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Therapy Type
 - 6.1. Introduction / Key Findings

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2. Historical Market Size Value (US\$ Bn) Analysis By Therapy Type, 2018-2022
- 6.3. Current and Future Market Size Value (US\$ Bn) Analysis and Forecast By Therapy Type, 2023-2033
 - 6.3.1. CAR T-cell Therapy
 - 6.3.2. T Cell Receptor (TCR)-based
 - 6.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
- 6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018-2022
- 6.5. Absolute \$ Opportunity Analysis By Therapy Type, 2023-2033
- 7. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Modality
 - 7.1. Introduction / Key Findings
 - 7.2. Historical Market Size Value (US\$ Bn) Analysis By Modality , 2018-2022
 - 7.3. Current and Future Market Size Value (US\$ Bn) Analysis and Forecast By Modality , 2023-2033
 - 7.3.1. Research
 - 7.3.2. Commercialized
 - 7.4. Y-o-Y Growth Trend Analysis By Modality , 2018-2022
 - 7.5. Absolute \$ Opportunity Analysis By Modality , 2023-2033
- 8. Global T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Region
 - 8.1. Introduction
 - 8.2. Historical Market Size Value (US\$ Bn) Analysis By Region, 2018-2022
 - 8.3. Current Market Size Value (US\$ Bn) Analysis and Forecast By Region, 2023-2033
 - 8.3.1. North America
 - 8.3.2. Latin America
 - 8.3.3. Europe
 - 8.3.4. Asia Pacific
 - 8.3.5. MEA
 - 8.4. Market Attractiveness Analysis By Region
- 9. North America T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
 - 9.1. Historical Market Size Value (US\$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
 - 9.2. Market Size Value (US\$ Bn) Forecast By Market Taxonomy, 2023-2033
 - 9.2.1. By Country
 - 9.2.1.1. U.S.
 - 9.2.1.2. Canada
 - 9.2.2. By Indication
 - 9.2.3. By Therapy Type
 - 9.2.4. By Modality
 - 9.3. Market Attractiveness Analysis
 - 9.3.1. By Country
 - 9.3.2. By Indication
 - 9.3.3. By Therapy Type
 - 9.3.4. By Modality
 - 9.4. Key Takeaways
- 10. Latin America T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
 - 10.1. Historical Market Size Value (US\$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
 - 10.2. Market Size Value (US\$ Bn) Forecast By Market Taxonomy, 2023-2033
 - 10.2.1. By Country
 - 10.2.1.1. Brazil
 - 10.2.1.2. Mexico
 - 10.2.1.3. Rest of Latin America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.2. By Indication
- 10.2.3. By Therapy Type
- 10.2.4. By Modality
- 10.3. Market Attractiveness Analysis
- 10.3.1. By Country
- 10.3.2. By Indication
- 10.3.3. By Therapy Type
- 10.3.4. By Modality
- 10.4. Key Takeaways
- 11. Europe T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
- 11.1. Historical Market Size Value (US\$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
- 11.2. Market Size Value (US\$ Bn) Forecast By Market Taxonomy, 2023-2033
- 11.2.1. By Country
- 11.2.1.1. Germany
- 11.2.1.2. Italy
- 11.2.1.3. France
- 11.2.1.4. U.K.
- 11.2.1.5. Spain
- 11.2.1.6. Russia
- 11.2.1.7. Rest of Europe
- 11.2.2. By Indication
- 11.2.3. By Therapy Type
- 11.2.4. By Modality
- 11.3. Market Attractiveness Analysis
- 11.3.1. By Country
- 11.3.2. By Indication
- 11.3.3. By Therapy Type
- 11.3.4. By Modality
- 11.4. Key Takeaways
- 12. Asia Pacific T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country
- 12.1. Historical Market Size Value (US\$ Bn) Trend Analysis By Market Taxonomy, 2018-2022
- 12.2. Market Size Value (US\$ Bn) Forecast By Market Taxonomy, 2023-2033
- 12.2.1. By Country
- 12.2.1.1. China
- 12.2.1.2. Japan
- 12.2.1.3. India
- 12.2.1.4. South Korea
- 12.2.1.5. Australia
- 12.2.1.6. Rest of APAC
- 12.2.2. By Indication
- 12.2.3. By Therapy Type
- 12.2.4. By Modality
- 12.3. Market Attractiveness Analysis
- 12.3.1. By Country
- 12.3.2. By Indication
- 12.3.3. By Therapy Type
- 12.3.4. By Modality

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

□□ 12.4. Key Takeaways

13. MEA T-cell Therapy Market Analysis 2018-2022 and Forecast 2023-2033, By Country

□□ 13.1. Historical Market Size Value (US\$ Bn) Trend Analysis By Market Taxonomy, 2018-2022

□□ 13.2. Market Size Value (US\$ Bn) Forecast By Market Taxonomy, 2023-2033

□□□□ 13.2.1. By Country

□□□□□□ 13.2.1.1. South Africa

□□□□□□ 13.2.1.2. Saudi Arabia

□□□□□□ 13.2.1.3. UAE

□□□□□□ 13.2.1.4. Israel

□□□□□□ 13.2.1.5. Rest of MEA

□□□□ 13.2.2. By Indication

□□□□ 13.2.3. By Therapy Type

□□□□ 13.2.4. By Modality

□□ 13.3. Market Attractiveness Analysis

□□□□ 13.3.1. By Country

□□□□ 13.3.2. By Indication

□□□□ 13.3.3. By Therapy Type

□□□□ 13.3.4. By Modality

□□ 13.4. Key Takeaways

14. Key Countries T-cell Therapy Market Analysis

□□ 14.1. U.S.

□□□□ 14.1.1. Pricing Analysis

□□□□ 14.1.2. Market Share Analysis, 2022

□□□□□□ 14.1.2.1. By Indication

□□□□□□ 14.1.2.2. By Therapy Type

□□□□□□ 14.1.2.3. By Modality

□□ 14.2. Canada

□□□□ 14.2.1. Pricing Analysis

□□□□ 14.2.2. Market Share Analysis, 2022

□□□□□□ 14.2.2.1. By Indication

□□□□□□ 14.2.2.2. By Therapy Type

□□□□□□ 14.2.2.3. By Modality

□□ 14.3. Brazil

□□□□ 14.3.1. Pricing Analysis

□□□□ 14.3.2. Market Share Analysis, 2022

□□□□□□ 14.3.2.1. By Indication

□□□□□□ 14.3.2.2. By Therapy Type

□□□□□□ 14.3.2.3. By Modality

□□ 14.4. Mexico

□□□□ 14.4.1. Pricing Analysis

□□□□ 14.4.2. Market Share Analysis, 2022

□□□□□□ 14.4.2.1. By Indication

□□□□□□ 14.4.2.2. By Therapy Type

□□□□□□ 14.4.2.3. By Modality

□□ 14.5. Germany

□□□□ 14.5.1. Pricing Analysis

□□□□ 14.5.2. Market Share Analysis, 2022

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.5.2.1. By Indication
- 14.5.2.2. By Therapy Type
- 14.5.2.3. By Modality
- 14.6. Italy
- 14.6.1. Pricing Analysis
- 14.6.2. Market Share Analysis, 2022
- 14.6.2.1. By Indication
- 14.6.2.2. By Therapy Type
- 14.6.2.3. By Modality
- 14.7. France
- 14.7.1. Pricing Analysis
- 14.7.2. Market Share Analysis, 2022
- 14.7.2.1. By Indication
- 14.7.2.2. By Therapy Type
- 14.7.2.3. By Modality
- 14.8. U.K.
- 14.8.1. Pricing Analysis
- 14.8.2. Market Share Analysis, 2022
- 14.8.2.1. By Indication
- 14.8.2.2. By Therapy Type
- 14.8.2.3. By Modality
- 14.9. Spain
- 14.9.1. Pricing Analysis
- 14.9.2. Market Share Analysis, 2022
- 14.9.2.1. By Indication
- 14.9.2.2. By Therapy Type
- 14.9.2.3. By Modality
- 14.10. Russia
- 14.10.1. Pricing Analysis
- 14.10.2. Market Share Analysis, 2022
- 14.10.2.1. By Indication
- 14.10.2.2. By Therapy Type
- 14.10.2.3. By Modality
- 14.11. China
- 14.11.1. Pricing Analysis
- 14.11.2. Market Share Analysis, 2022
- 14.11.2.1. By Indication
- 14.11.2.2. By Therapy Type
- 14.11.2.3. By Modality
- 14.12. Japan
- 14.12.1. Pricing Analysis
- 14.12.2. Market Share Analysis, 2022
- 14.12.2.1. By Indication
- 14.12.2.2. By Therapy Type
- 14.12.2.3. By Modality
- 14.13. India
- 14.13.1. Pricing Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.13.2. Market Share Analysis, 2022
 - 14.13.2.1. By Indication
 - 14.13.2.2. By Therapy Type
 - 14.13.2.3. By Modality
- 14.14. South Korea
 - 14.14.1. Pricing Analysis
 - 14.14.2. Market Share Analysis, 2022
 - 14.14.2.1. By Indication
 - 14.14.2.2. By Therapy Type
 - 14.14.2.3. By Modality
- 14.15. Australia
 - 14.15.1. Pricing Analysis
 - 14.15.2. Market Share Analysis, 2022
 - 14.15.2.1. By Indication
 - 14.15.2.2. By Therapy Type
 - 14.15.2.3. By Modality
- 14.16. South Africa
 - 14.16.1. Pricing Analysis
 - 14.16.2. Market Share Analysis, 2022
 - 14.16.2.1. By Indication
 - 14.16.2.2. By Therapy Type
 - 14.16.2.3. By Modality
- 14.17. Saudi Arabia
 - 14.17.1. Pricing Analysis
 - 14.17.2. Market Share Analysis, 2022
 - 14.17.2.1. By Indication
 - 14.17.2.2. By Therapy Type
 - 14.17.2.3. By Modality
- 14.18. UAE
 - 14.18.1. Pricing Analysis
 - 14.18.2. Market Share Analysis, 2022
 - 14.18.2.1. By Indication
 - 14.18.2.2. By Therapy Type
 - 14.18.2.3. By Modality
- 14.19. Israel
 - 14.19.1. Pricing Analysis
 - 14.19.2. Market Share Analysis, 2022
 - 14.19.2.1. By Indication
 - 14.19.2.2. By Therapy Type
 - 14.19.2.3. By Modality
- 15. Market Structure Analysis
 - 15.1. Competition Dashboard
 - 15.2. Competition Benchmarking
 - 15.3. Market Share Analysis of Top Players
 - 15.3.1. By Regional
 - 15.3.2. By Indication
 - 15.3.3. By Therapy Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

□□□□ 15.3.4. By Modality

16. Competition Analysis

□□ 16.1. Competition Deep Dive

□□□□ 16.1.1. Novartis AG

□□□□□□ 16.1.1.1. Overview

□□□□□□ 16.1.1.2. Product Portfolio

□□□□□□ 16.1.1.3. Profitability by Market Segments

□□□□□□ 16.1.1.4. Sales Footprint

□□□□□□ 16.1.1.5. Strategy Overview

□□□□□□□□ 16.1.1.5.1. Marketing Strategy

□□□□□□□□ 16.1.1.5.2. Product Strategy

□□□□□□□□ 16.1.1.5.3. Channel Strategy

□□□□ 16.1.2. Merck KGaA

□□□□□□ 16.1.2.1. Overview

□□□□□□ 16.1.2.2. Product Portfolio

□□□□□□ 16.1.2.3. Profitability by Market Segments

□□□□□□ 16.1.2.4. Sales Footprint

□□□□□□ 16.1.2.5. Strategy Overview

□□□□□□□□ 16.1.2.5.1. Marketing Strategy

□□□□□□□□ 16.1.2.5.2. Product Strategy

□□□□□□□□ 16.1.2.5.3. Channel Strategy

□□□□ 16.1.3. Gilead Sciences Inc.

□□□□□□ 16.1.3.1. Overview

□□□□□□ 16.1.3.2. Product Portfolio

□□□□□□ 16.1.3.3. Profitability by Market Segments

□□□□□□ 16.1.3.4. Sales Footprint

□□□□□□ 16.1.3.5. Strategy Overview

□□□□□□□□ 16.1.3.5.1. Marketing Strategy

□□□□□□□□ 16.1.3.5.2. Product Strategy

□□□□□□□□ 16.1.3.5.3. Channel Strategy

□□□□ 16.1.4. TCR2 Therapeutics Inc

□□□□□□ 16.1.4.1. Overview

□□□□□□ 16.1.4.2. Product Portfolio

□□□□□□ 16.1.4.3. Profitability by Market Segments

□□□□□□ 16.1.4.4. Sales Footprint

□□□□□□ 16.1.4.5. Strategy Overview

□□□□□□□□ 16.1.4.5.1. Marketing Strategy

□□□□□□□□ 16.1.4.5.2. Product Strategy

□□□□□□□□ 16.1.4.5.3. Channel Strategy

□□□□ 16.1.5. Bluebird Bio Inc

□□□□□□ 16.1.5.1. Overview

□□□□□□ 16.1.5.2. Product Portfolio

□□□□□□ 16.1.5.3. Profitability by Market Segments

□□□□□□ 16.1.5.4. Sales Footprint

□□□□□□ 16.1.5.5. Strategy Overview

□□□□□□□□ 16.1.5.5.1. Marketing Strategy

□□□□□□□□ 16.1.5.5.2. Product Strategy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.5.5.3. Channel Strategy
- 16.1.6. Sorrento Therapeutics
- 16.1.6.1. Overview
- 16.1.6.2. Product Portfolio
- 16.1.6.3. Profitability by Market Segments
- 16.1.6.4. Sales Footprint
- 16.1.6.5. Strategy Overview
- 16.1.6.5.1. Marketing Strategy
- 16.1.6.5.2. Product Strategy
- 16.1.6.5.3. Channel Strategy
- 16.1.7. Fate Therapeutics
- 16.1.7.1. Overview
- 16.1.7.2. Product Portfolio
- 16.1.7.3. Profitability by Market Segments
- 16.1.7.4. Sales Footprint
- 16.1.7.5. Strategy Overview
- 16.1.7.5.1. Marketing Strategy
- 16.1.7.5.2. Product Strategy
- 16.1.7.5.3. Channel Strategy
- 16.1.8. Pfizer Inc
- 16.1.8.1. Overview
- 16.1.8.2. Product Portfolio
- 16.1.8.3. Profitability by Market Segments
- 16.1.8.4. Sales Footprint
- 16.1.8.5. Strategy Overview
- 16.1.8.5.1. Marketing Strategy
- 16.1.8.5.2. Product Strategy
- 16.1.8.5.3. Channel Strategy
- 16.1.9. Amgen
- 16.1.9.1. Overview
- 16.1.9.2. Product Portfolio
- 16.1.9.3. Profitability by Market Segments
- 16.1.9.4. Sales Footprint
- 16.1.9.5. Strategy Overview
- 16.1.9.5.1. Marketing Strategy
- 16.1.9.5.2. Product Strategy
- 16.1.9.5.3. Channel Strategy
- 16.1.10. Celgene Corporation
- 16.1.10.1. Overview
- 16.1.10.2. Product Portfolio
- 16.1.10.3. Profitability by Market Segments
- 16.1.10.4. Sales Footprint
- 16.1.10.5. Strategy Overview
- 16.1.10.5.1. Marketing Strategy
- 16.1.10.5.2. Product Strategy
- 16.1.10.5.3. Channel Strategy
- 17. Assumptions & Acronyms Used

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumours and Other Indications), by Therapy Type (CAR T-cell Therapy, TCR-based and TIL-based), by Modality (Research and Commercialized) and Region - 2023 to 2033

Market Report | 2023-01-19 | 250 pages | Transparency Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5795.00
	Multi User License	\$8795.00
	Global Site License	\$11795.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.